CytoMed Therapeutics vs Quantum Cyber
GDTC and QUCY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GDTC and QUCY compare
CytoMed Therapeutics grew revenue faster over the last twelve months (367% versus −39.9% for Quantum Cyber).
CytoMed Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1227% compared with −3018% at Quantum Cyber.
CytoMed Therapeutics scores higher on the StockData Score (4 against 3 for Quantum Cyber), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GDTC | QUCY |
|---|---|---|
| Size and price | ||
| Share price | $0.774 | $0.630 |
| Change, 1 year | −59.7% | −53.7% |
| Change, 5 years | – | −93.6% |
| Beta (5Y) | −0.40 | – |
| Employees | 5 | 3 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 367% (better) | −39.9% |
| Revenue growth, 5Y average | – | 1.7% |
| Profitability | ||
| Gross margin | – | 72.6% |
| Operating margin | – | −3005% |
| Net margin | −1227% (better) | −3018% |
| FCF margin | −1336% (better) | −2045% |
| Return on equity | −51.3% (better) | −141% |
| Return on invested capital | – | −324% |
| Financial health | ||
| Debt / equity | 0.06 | – |
| Interest coverage | – | −43.2× |
| Current ratio | 5.17 | 5.56 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Ownership | ||
| Held by institutions | 0.10% | 2.4% |
| Held by insiders | 25.9% | – |
| Insider net buying, 12 months | $729K (better) | $0 |
Go deeper
- GDTC stock overview
- GDTC income statement
- GDTC valuation and score
- QUCY stock overview
- QUCY income statement
- QUCY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.